Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brenetafusp + nivolumab
- Development stage
- Unknown
- Lead developer
- Immunocore
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Brenetafusp + nivolumab** is an investigational combination therapy for advanced or metastatic cutaneous melanoma in HLA-A*02:01–positive patients. **Brenetafusp** (IMC-F106C) is a bispecific ImmTAC (immune-mobilizing monoclonal T-cell receptor against cancer) fusion protein that targets the PRAME (preferentially expressed antigen in melanoma) antigen presented by HLA-A*02:01 molecules. It redirects T cells to kill PRAME-expressing cancer cells. **Nivolumab** is a monoclonal antibody checkpoint inhibitor targeting PD-1, restoring T cell activity against tumors. This combination aims to enhance anti-tumor immune responses by combining targeted T cell redirection with immune checkpoint blockade. Developed primarily for first-line treatment of advanced melanoma, it is currently being evaluated in the global phase 3 PRISM-MEL-301 trial.
- Brand names
- Opdivo
- Other names
- brenetafusp + nivolumabIMC-F106C + nivolumabPRAME-A02 + nivolumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on brenetafusp + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brenetafusp + nivolumab.